

## Lorus Therapeutics Inc. Due Diligence Report Including Financial, SWOT, Competitors and Industry Analysis

URL:	<a href="https://marketpublishers.com/r/LA86F6F20CFBEN.html">https://marketpublishers.com/r/LA86F6F20CFBEN.html</a>
Date:	August 15, 2018
Pages:	50
Price:	US\$ 499.00
ID:	LA86F6F20CFBEN

Lorus Therapeutics Inc. Due Diligence Report provides a complete overview of the company's affairs. All available data is presented in a comprehensive and easily accessed format. The report includes financial and SWOT information, industry analysis, opinions, estimates, plus annual and quarterly forecasts made by stock market experts. The report also enables direct comparison to be made between Lorus Therapeutics Inc. and its competitors. This provides our Clients with a clear understanding of Lorus Therapeutics Inc. position in the **Pharmaceuticals and Biotechnology Industry**.

- The report contains detailed information about Lorus Therapeutics Inc. that gives an unrivalled in-depth knowledge about internal business-environment of the company: data about the owners, senior executives, locations, subsidiaries, markets, products, and company history.
- Another part of the report is a SWOT-analysis carried out for Lorus Therapeutics Inc.. It involves specifying the objective of the company's business and identifies the different factors that are favorable and unfavorable to achieving that objective. SWOT-analysis helps to understand company's strengths, weaknesses, opportunities, and possible threats against it.
- The Lorus Therapeutics Inc. financial analysis covers the income statement and ratio trend-charts with balance sheets and cash flows presented on an annual and quarterly basis. The report outlines the main financial ratios pertaining to profitability, margin analysis, asset turnover, credit ratios, and company's long-term solvency. This sort of company's information will assist and strengthen your company's decision-making processes.
- In the part that describes Lorus Therapeutics Inc. competitors and the industry in whole, the information about company's financial ratios is compared to those of its competitors and to the industry. The unique analysis of the market and company's competitors along with detailed information about the internal and external factors affecting the relevant industry will help to manage your business environment. Your company's business and sales activities will be boosted by gaining an insight into your competitors' businesses.
- Also the report provides relevant news, an analysis of PR-activity, and stock price movements. The latter are correlated with pertinent news and press releases, and annual and quarterly forecasts are given by a variety of experts and market research firms. Such information creates your awareness about principal trends of Lorus Therapeutics Inc. business.

### About Lorus Therapeutics Inc.

Lorus Therapeutics Inc., a biopharmaceutical company, focuses on the discovery, research, and development of anticancer therapies in Canada.

The company has product candidates in three classes of anticancer therapies: RNA-targeted therapies; small molecule therapies; and immunotherapeutics. It has commercial rights in Virulizin.

## RNA-Targeted Therapies

The company's RNA-targeted drugs consist of antisense drugs and short-interfering RNA (siRNA). The premise of this therapeutic approach is to target an earlier stage of the biochemical process than is usually possible with conventional drugs. The blueprint for protein production is encoded in the DNA of each cell. To translate this code into protein the cell first produces mRNAs (messenger ribonucleic acids) specific to each protein and these act as intermediaries between the information encoded in DNA and production of the corresponding protein.

**LOR-2040:** The company has developed various antisense drugs, of which its principal product is LOR-2040 (formerly GTI-2040). LOR-2040 targets the R2 component of ribonucleotide reductase (RNR) and has exhibited antitumor properties against over different human cancers in standard mouse models, including chemotherapy resistant tumors. It has completed a Phase I/II clinical trial of LOR-2040 for advanced or metastatic renal cell carcinoma. It is also conducting or has completed multiple Phase I/II clinical trial programs in cooperation with the U.S. National Cancer Institute (NCI), for the study of LOR-2040 for the treatment of acute myeloid leukemia (AML), breast cancer, lung cancer, colon cancer, prostate cancer, a series of solid tumors and myelodysplastic syndrome, and acute leukemia.

**LOR-1284:** LOR-1284 (formerly siRNA-1284), the principal compound identified from the screening study, targets R2 expression. In vitro studies, down-regulation of R2 expression by LOR-1284 resulted in decreased tumor cell growth (proliferation) with a concomitant block in cell cycle progression. LOR-1284 demonstrates anti-tumor activity against human kidney, skin, and colon cancers in mouse experimental models of tumor growth.

## Small Molecule Therapies

Chemical compounds weighing less than 1000 daltons (a unit of molecular weight) are designated as small or low molecular weight molecules. These molecules can be designed to target specific proteins or receptors that are known to be involved with disease.

**LOR-253:** The company has selected two small molecule compounds from a series of novel small molecules discovered, which exhibit potent anticancer activity in vitro screens. It has developed LOR-253 as a principal compound for the treatment of colon carcinoma and non-small cell lung cancer. It has completed formal good lab practises (GLP) toxicology studies for LOR-253. In June 2010, the company completed the filing of an investigational new drug application with the FDA which was for a first-in-man Phase I dose escalation trial in advanced or metastatic solid tumors.

The company is pursuing other candidates at earlier stages of development. These include ÿ LOR-264, a second generation LOR-253 derivative, is being developed for oral administration. Like LOR-253, LOR-264 has demonstrated potent anticancer activity in animal studies and represents the oral drug in this development platform; ÿ LOR-500 targets multikinases, including tyrosine kinase family members and a member of the calcium/calmodulin dependent protein kinase family; and ÿ LOR-220 platform, a compound that targets novel bacterial Ser/Thr kinases.

## Immunotherapy

Immunotherapy is a form of treatment that stimulates the body's immune system to fight diseases, including cancer.

**Interleukin-17E:** Interleukin-17E (IL-17E) is a protein-based therapeutic that it is developing as an immunotherapy for cancer treatment. It has shown that IL-17E has anticancer activity against a range of human cancers. IL-17E had antitumor activity in various solid tumors, including melanoma, breast, colon, pancreatic, and non-small cell lung cancers.

**Virulizin:** In 2008, the company entered into a licensing deal with a subsidiary of Zoticon Bioventures'

subsidiary, ZOR Pharmaceuticals, LLC, for Virulizin. The license, covering north and south America, Europe, and Israel. In addition, its wholly-owned subsidiary received a 25% equity interest in ZOR Pharmaceuticals, LLC. Zor is responsible for clinical developments, regulatory submissions, and commercial activities.

#### License Agreements

Ion Pharmaceuticals: The company, through NuChem Pharmaceuticals Inc., acquired patent rights and a sublicense from Ion to develop and commercialize the anticancer applications of CLT and new chemical entities related to CLT (the NuChem Analogs).

#### Collaboration Agreements

Zoticon Bioventures Inc.: The company, through its wholly owned subsidiary, GeneSense Technologies Inc., signed a multinational license agreement with ZOR Pharmaceuticals, LLC formed as a subsidiary of Zoticon Bioventures Inc., to develop and commercialize Virulizin for human therapeutic applications.

National Cancer Institute: The company and the NCI approved clinical protocols to conduct a series of clinical trials in a phase I/II program to investigate the safety and efficacy of LOR-2040. It and the NCI signed a formal clinical trial agreement in which the NCI financially sponsors the LOR-2040 clinical trials, while it provides the clinical trial drug. In 2009, the company entered into an additional agreement with the NCI for the study of LOR-2501, LOR- 2040, and LOR-1284 in combination with commercially-available drugs, to develop a drug cocktail(s) that is for the treatment of Renal Cell Carcinoma tumors than for normal regenerating kidney.

#### History

Lorus Therapeutics Inc. was founded in 1986.

The above Company Fundamental Report is a half-ready report and contents are subject to change. It means that we have all necessary data in our database to prepare the report but need **2-3 days** to complete it. During this time we are also updating the report with respect to the current moment. So, you can get all the most recent data available for the same price. Please note that preparation of additional types of analyses requires extra time.

## Table of Content

### RESEARCH METHODOLOGY

### DISCLAIMER

## 1. LORUS THERAPEUTICS INC. COMPANY PROFILE

- 1.1. Key facts
- 1.2. Financial Performance
- 1.3. Key Executives
- 1.4. Ownership and Major Holders
- 1.5. Company History

## 2. LORUS THERAPEUTICS INC. BUSINESS OVERVIEW

- 2.1. Business Description
- 2.2. Major Products and Services
- 2.3. Markets and Sales Activities

#### 2.4. Locations, Subsidiaries, Operating Units

### **3. LORUS THERAPEUTICS INC. SWOT ANALYSIS**

- 3.1. Overview
- 3.2. Strengths
- 3.3. Weaknesses
- 3.4. Opportunities
- 3.5. Threats

### **4. LORUS THERAPEUTICS INC. FINANCIAL ANALYSIS**

- 4.1. Financial Statements
  - 4.1.1. Income Statement
  - 4.1.2. Balance Sheet
  - 4.1.3. Cash Flow
- 4.2. Financial Ratios
  - 4.2.1. Profitability
  - 4.2.2. Margin Analysis
  - 4.2.3. Asset Turnover
  - 4.2.4. Credit Ratios
  - 4.2.5. Long-Term Solvency
  - 4.2.6. Growth Over Prior Year
  - 4.2.7. Financial Ratios Charts
- 4.3. Stock Market Snapshot

### **5. LORUS THERAPEUTICS INC. COMPETITORS AND INDUSTRY ANALYSIS**

- 5.1. Lorus Therapeutics Inc. Direct Competitors
- 5.2. Comparison of Lorus Therapeutics Inc. and Direct Competitors Financial Ratios
- 5.3. Comparison of Lorus Therapeutics Inc. and Direct Competitors Stock Charts
- 5.4. Lorus Therapeutics Inc. Industry Analysis
  - 5.4.1. Pharmaceuticals and Biotechnology Industry Snapshot
  - 5.4.2. Lorus Therapeutics Inc. Industry Position Analysis

### **6. LORUS THERAPEUTICS INC. NEWS & EVENTS**

- 6.1. News & PR Activity Analysis
- 6.2. IR Corporate News
- 6.3. Marketing News
- 6.4. Corporate Events

### **7. LORUS THERAPEUTICS INC. EXPERTS REVIEW<sup>1</sup>**

- 7.1. Experts Opinion
- 7.2. Experts Estimates

### **8. LORUS THERAPEUTICS INC. ENHANCED SWOT ANALYSIS<sup>2</sup>**

### **9. CANADA PESTEL ANALYSIS<sup>2</sup>**

- 9.1. Political Factors
- 9.2. Economic Factors
- 9.3. Social Factors
- 9.4. Technological Factors

9.5. Environmental Factors

9.6. Legal Factors

## **10. LORUS THERAPEUTICS INC. IFE, EFE, IE MATRICES<sup>2</sup>**

10.1. Internal Factor Evaluation Matrix

10.2. External Factor Evaluation Matrix

10.3. Internal External Matrix

## **11. LORUS THERAPEUTICS INC. PORTER FIVE FORCES ANALYSIS<sup>2</sup>**

## **12. LORUS THERAPEUTICS INC. VRIO ANALYSIS<sup>2</sup>**

### **APPENDIX: RATIO DEFINITIONS**

#### **LIST OF TABLES**

Lorus Therapeutics Inc. Key Facts

Profitability

Management Effectiveness

Income Statement Key Figures

Balance Sheet Key Figures

Cash Flow Statement Key Figures

Financial Performance Abbreviation Guide

Lorus Therapeutics Inc. Key Executives

Key Executives Biographies<sup>1</sup>

Key Executives Compensations<sup>1</sup>

Lorus Therapeutics Inc. Major Shareholders

Lorus Therapeutics Inc. History

Lorus Therapeutics Inc. Products

Revenues by Segment

Revenues by Region

Lorus Therapeutics Inc. Offices and Representations

Lorus Therapeutics Inc. SWOT Analysis

Yearly Income Statement Including Trends

Income Statement Latest 4 Quarters Including Trends

Yearly Balance Sheet Including Trends

Balance Sheet Latest 4 Quarters Including Trends

Yearly Cash Flow Including Trends

Cash Flow Latest 4 Quarters Including Trends

Lorus Therapeutics Inc. Profitability Ratios

Margin Analysis Ratios

Asset Turnover Ratios

Credit Ratios

Long-Term Solvency Ratios

Financial Ratios Growth Over Prior Year

Lorus Therapeutics Inc. Capital Market Snapshot

Lorus Therapeutics Inc. Direct Competitors Key Facts

Direct Competitors Profitability Ratios

Direct Competitors Margin Analysis Ratios

Direct Competitors Asset Turnover Ratios

Direct Competitors Credit Ratios

Direct Competitors Long-Term Solvency Ratios

Pharmaceuticals and Biotechnology Industry Statistics

Lorus Therapeutics Inc. Industry Position

Company vs. Industry Income Statement Analysis  
Company vs. Industry Balance Sheet Analysis  
Company vs. Industry Cash Flow Analysis  
Company vs. Industry Ratios Comparison  
Lorus Therapeutics Inc. Consensus Recommendations<sup>1</sup>  
Analyst Recommendation Summary<sup>1</sup>  
Price Target Summary<sup>1</sup>  
Experts Recommendation Trends<sup>1</sup>  
Revenue Estimates Analysis<sup>1</sup>  
Earnings Estimates Analysis<sup>1</sup>  
Historical Surprises<sup>1</sup>  
Revenue Estimates Trend<sup>1</sup>  
Earnings Estimates Trend<sup>1</sup>  
Revenue Revisions<sup>1</sup>

## LIST OF FIGURES

Lorus Therapeutics Inc. Annual Revenues in Comparison with Cost of Goods Sold and Gross Profit Profit Margin Chart  
Operating Margin Chart  
Return on Equity (ROE) Chart  
Return on Assets (ROA) Chart  
Debt to Equity Chart  
Current Ratio Chart  
Lorus Therapeutics Inc. 1-year Stock Charts  
Lorus Therapeutics Inc. 5-year Stock Charts  
Lorus Therapeutics Inc. vs. Main Indexes 1-year Stock Chart  
Lorus Therapeutics Inc. vs. Direct Competitors 1-year Stock Charts  
Lorus Therapeutics Inc. Article Density Chart

<sup>1</sup> – Data availability depends on company's security policy.

<sup>2</sup> – These sections are available only when you purchase a report with appropriate additional types of analyses.

The complete financial data is available for publicly traded companies.

### I would like to order:

**Product name:** Lorus Therapeutics Inc. Due Diligence Report Including Financial, SWOT, Competitors and Industry Analysis  
**Product link:** <https://marketpublishers.com/r/LA86F6F20CFBEN.html>  
**Product ID:** LA86F6F20CFBEN  
**Price:** US\$ 499.00 (Single User License / Electronic Delivery)

*If you want to order Corporate License or Hard Copy, please, contact our Customer Service: [office@marketpublishers.com](mailto:office@marketpublishers.com)*

### Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click 'BUY NOW' button on product page <https://marketpublishers.com/r/LA86F6F20CFBEN.html>

### To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
E-mail:  
Company:  
Address:  
City:  
Zip/Post Code:  
Country:  
Tel:  
Fax:  
Your message:

\* All fields are required

Customer Signature \_\_\_\_\_

Please, note that by ordering from MarketPublisher.com you are agreeing to our Terms & Conditions at [https://marketpublishers.com/docs/terms\\_conditions.html](https://marketpublishers.com/docs/terms_conditions.html)

To place an order via fax simply print this form, fill in the information below and fax the completed form to **+44 20 7900 3970**